Clinical trials: Second-Line
Colorectal Cancer
A Study in Second Line Metastatic Colorectal Cancer
The purpose of this study is to compare overall survival in participants with metastatic colorectal cancer treated with either ramucirumab and FOLFIRI or placebo and FOLFIRI.
- Trial name
- NCT01183780
- Testing
- Ramucirumab, Irinotecan, Folinic Acid
- Where
- 213 sites in United States, Argentina and 24 more
- Volunteers
- 1,072 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Small Cell
BI 2536 Second Line Monotherapy in SCLC
Open label, uncontrolled Phase II trial to assess the efficacy and safety of BI 2536 in second line treatment in sensitive-relapse SCLC patients.
- Trial name
- NCT00412880
- Testing
- BI 2536
- Where
- 10 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer, Non-Small Cell Lung Cancer
A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia
The purpose of this study is to investigate the safety of patients in Asia with Non-Small Cell Lung Cancer (NSCLC)who are treated with Nivolumab monotherapy as a second line or third line treatment.
- Trial name
- CheckMate870 (NCT03195491)
- Testing
- Nivolumab
- Where
- 30 sites in China, Thailand
- Volunteers
- 400 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
This phase I/II trial studies the side effects and best dose of IDO1 inhibitor BMS-986205 (BMS-986205) when given together with nivolumab and how well it works as first or second line therapy in treating patients with liver…
- Conditions
- Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT03695250
- Testing
- IDO1 Inhibitor BMS-986205, Nivolumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Edward Kim
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
This randomized phase II trial studies how well modified irinotecan hydrochloride, leucovorin calcium, fluorouracil (FOLFIRI) and veliparib as a second line of therapy work compared to FOLFIRI in treating patients with pancreatic…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT02890355
- Testing
- Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 783 sites in United States
- Volunteers
- 123 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma
Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
This study will evaluate everolimus as second-line therapy in patients with metastatic renal cell carcinoma. Each patient will be enrolled and stratified in one of three cohorts based upon their first-line therapy: 1) prior…
- Trial name
- RECORD-4 (NCT01491672)
- Testing
- RAD001
- Where
- 17 sites in United States, Argentina and 4 more
- Volunteers
- 134 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Neoplasms
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
The primary purpose of this protocol is to determine the activity of AG 013736 in patients with metastatic renal cell cancer who have received 1 prior cytokine-based therapy.
- Trial name
- NCT00076011
- Testing
- Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor
- Where
- 9 sites in United States, France and 1 more
- Volunteers
- 52 people
- Sponsor
- Pfizer
Recurrent Small-cell Lung Cancer (SCLC), Lung Cancer, Small Cell
Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer
Combination of Hycamtin (topotecan) and Avastin (bevacizumab) could allow killing of both endothelial and neoplastic cells. We postulate that addition of bevacizumab to topotecan will increase delivery of topotecan to tumor cells…
- Trial name
- NCT00698516
- Testing
- Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)
- Where
- 16 sites in United States
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Epithelial Ovarian Cancer
Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment
As < 10% of the necessary patients required by the protocol were recruited and the data were not intended to support a labeling claim, it was determined that the abbreviated clinical study report (CSR) was the appropriate…
- Trial name
- CANVAS (NCT01521143)
- Testing
- Cvac
- Where
- 8 sites in United States, Australia
- Volunteers
- 91 people
- Sponsor
- Prima BioMed Ltd
Endometrial Cancer
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Open-label, randomized, active-controlled, two-arm Phase III study to compare the efficacy and safety of AEZS-108 and doxorubicin.
- Trial name
- ZoptEC (NCT01767155)
- Testing
- AEZS-108 / zoptarelin doxorubicin, doxorubicin
- Where
- 123 sites in United States, Austria and 20 more
- Volunteers
- 511 people
- Sponsor
- AEterna Zentaris
Pancreatic Cancer
Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer
To compare the efficacy of pegilodecakin in combination with FOLFOX versus FOLFOX alone in participants with metastatic pancreatic cancer as measured by overall survival.
- Trial name
- Sequoia (NCT02923921)
- Testing
- Pegilodecakin, FOLFOX
- Where
- 130 sites in United States, Australia and 11 more
- Volunteers
- 567 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
This is a Phase 3 multicenter, randomized study evaluating the safety and efficacy of ramucirumab DP plus BSC as a double-blind, placebo-controlled (placebo plus BSC) comparison.
- Trial name
- REACH (NCT01140347)
- Testing
- Ramucirumab DP (IMC-1121B), BSC
- Where
- 146 sites in United States, Australia and 25 more
- Volunteers
- 565 people
- Sponsor
- Eli Lilly and Company
Cancer
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
This was a randomized, open-label, multi-center Phase III study evaluating the efficacy and safety of lapatinib in combination with trastuzumab versus trastuzumab alone as continued HER2 suppression therapy in women with…
- Trial name
- NCT00968968
- Testing
- Lapatinib, Trastuzumab
- Where
- 116 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Ulcerative Colitis
Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis
The purpose of this study is to determine whether a diet intervention (the Fasting Mimicking diet) will help induce clinical and biochemical response to an advanced therapy in patients with ulcerative colitis.
- Trial name
- NCT04505410
- Testing
- A plant based high fiber diet that mimics fasting ("FMD") plus advanced therapy, Advanced therapy only without dietary intervention
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Miami
Colorectal Cancer
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
The purpose of the Phase Ib portion is to find out the highest dose of study drug that can safely be given when tested in a small group of subjects.
- Trial name
- NCT01133990
- Testing
- FOLFIRI, E7820, Bevacizumab
- Where
- 34 sites in United States, Australia and 3 more
- Volunteers
- 5 people
- Sponsor
- Eisai Inc.
Non-small Cell Lung Cancer
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
This is a multi-center, open-label, randomized, Phase 1b/2 study to determine the recommended phase 2 dose (RP2D) and to evaluate the efficacy in terms of progression free survival (PFS) of Tepotinib when used in combination with…
- Trial name
- NCT01982955
- Testing
- Tepotinib, Gefitinib, Pemetrexed
- Where
- 44 sites in China, Italy and 5 more
- Volunteers
- 88 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced Renal Cell Carcinoma
AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib
This phase 2 study is an open-label, multi-center study to determine the safety and tolerability of AMG 386 in combination with sunitinib in the treatment of subjects with metastatic renal cell carcinoma.
- Trial name
- NCT00853372
- Testing
- Sunitinib, Trebananib
- Volunteers
- 85 people
- Sponsor
- Amgen
Hepatocellular Carcinoma
Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)
This is a study of pembrolizumab (MK-3475) in participants with previously systemically treated advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT02702401
- Testing
- Pembrolizumab, Best Supportive Care
- Volunteers
- 413 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Cancer
E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125
The purpose of this study was to determine the maximum tolerated dose (MTD)/recommended Phase II dose of lenvatinib administered in combination with carboplatin and gemcitabine (Phase IB) and to evaluate the safety and…
- Trial name
- NCT01133756
- Testing
- Lenvatinib, Carboplatin, Gemcitabine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Eisai Inc.
Non-Small-Cell Lung Cancer
A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer
The purpose of this study is to compare the combination of erlotinib and pemetrexed versus either pemetrexed alone and erlotinib alone, in terms of progression-free survival (time until the objective worsening of the disease) in…
- Trial name
- NCT00550173
- Testing
- pemetrexed, erlotinib
- Where
- 29 sites in Brazil, China and 5 more
- Volunteers
- 247 people
- Sponsor
- Eli Lilly and Company